Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 06'th Mar 2024
NEWARK, CA / ACCESSWIRE / March 6, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that they will participate in three upcoming investor conferences: Event: 2024
4 Must-Buy Stocks for Remarkable Earnings Acceleration
08:06am, Monday, 04'th Mar 2024
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).
Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?
01:21pm, Friday, 01'st Mar 2024
Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice
01:01pm, Friday, 01'st Mar 2024
Does Protagonist Therapeutics (PTGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Friday, 01'st Mar 2024
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade
10:56am, Friday, 01'st Mar 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 37.2% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questio
Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why
09:51am, Friday, 01'st Mar 2024
Protagonist Therapeutics (PTGX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that mad
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 27'th Feb 2024
Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications Cash runway ext
- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy - Rusfertide was associated with
Protagonist Therapeutics Reports Granting of Inducement Awards
04:05pm, Tuesday, 20'th Feb 2024
NEWARK, CA / ACCESSWIRE / February 20, 2024 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on February 15, 2024, it issued inducement awards to Sid Reddy, the Company's recently hi
JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. NEWARK, CA / ACC
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
02:06pm, Friday, 02'nd Feb 2024
Per the deal, Protagonist (PTGX) will grant exclusive rights to Takeda to market its late-stage rare hematology drug. In return, Takeda will make an upfront payment of $300 million.
Protagonist Therapeutics: On A Ship That Could Be About To Sail
01:03am, Friday, 08'th Dec 2023
Protagonist Therapeutics is developing two parallel programs in different disease areas and has recovered in market valuation. The company will present important data on hematocrit control and iron de
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
07:30am, Wednesday, 01'st Nov 2023
NEWARK, CA / ACCESSWIRE / November 1, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics: There Are Reasons Behind Johnson & Johnson's Optimism
03:35pm, Friday, 22'nd Sep 2023
Protagonist Therapeutics, Inc.'s oral IL-23 drug for psoriasis, JNJ-2113, must show non-inferior efficacy to Johnson & Johnson's injectable Tremfya before further development. JNJ-2113 is the only ora
